The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okamoto, I.
Right arrow Articles by Kurimoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okamoto, I.
Right arrow Articles by Kurimoto, M.
The Journal of Immunology, 2000, 164: 6067-6074.
Copyright © 2000 by The American Association of Immunologists

IL-18 Prevents the Development of Chronic Graft-Versus-Host Disease in Mice

Iwao Okamoto1, Keizo Kohno, Tadao Tanimoto, Kansou Iwaki, Tatsuya Ishihara, Sachiko Akamatsu, Hakuo Ikegami and Masashi Kurimoto

Fujisaki Institute, Hayashibara Biochemical Laboratories, Inc., Okayama, Japan

The development of chronic graft-versus-host disease (GVHD), which is induced by the transfer of DBA/2 spleen cells into (C57BL/6 x DBA/2)F1 (BDF1) mice, is closely related to diminished donor anti-host CTL activity and host B cell hyperactivation. Therefore, an approach which activates donor CD8+ T cells or suppresses donor CD4+ T cell-host B cell interaction may have clinical utility in the treatment of chronic GVHD. We have previously demonstrated that IL-18 induces the development of naive CD8+ T cells into type I effector cells in DBA/2 anti-BDF1 MLC. In this paper we examined the effect of IL-18 administration on the development of chronic GVHD in mice. The treatment was started before or after the onset of clinical evidence of the disease. Regardless of the treatment schedule, IL-18 significantly decreased immunological parameters indicative of chronic GVHD, such as elevated serum IgG antinuclear Abs, IgG1, and IgE levels, and host B cell numbers and their activation. Importantly, IL-18-treated mice did not show the same acute GVHD-like symptoms reported for IL-12 treatment, because there was no weight loss, death, or severe immunodeficiency as indicated by a decrease in IL-2 and IFN-{gamma} production by Con A-stimulated spleen cells. In contrast, IL-18 treatment partially but significantly restored the production of these cytokines. Data further suggested that these IL-18-mediated therapeutic effects may be due to the induction of donor CD8+ CTL, the decrease in donor CD4+ T cell numbers, and a down-regulation of host B cell MHC class II expression. Thus, our results suggest that IL-18 has beneficial effects in the prevention and treatment of chronic GVHD.




This article has been cited by other articles:


Home page
 BloodHome page
G. Socie and B. R. Blazar
Acute graft-versus-host disease: from the bench to the bedside
Blood, November 12, 2009; 114(20): 4327 - 4336.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C.-K. Min, Y. Maeda, K. Lowler, C. Liu, S. Clouthier, D. Lofthus, E. Weisiger, J. L. M. Ferrara, and P. Reddy
Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation
Blood, November 15, 2004; 104(10): 3393 - 3399.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
T. Iwasaki
Recent Advances in the Treatment of Graft-Versus-Host Disease
Clin. Med. Res., November 1, 2004; 2(4): 243 - 252.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Leung, R. Iyengar, V. Turner, P. Lang, P. Bader, P. Conn, D. Niethammer, and R. Handgretinger
Determinants of Antileukemia Effects of Allogeneic NK Cells
J. Immunol., January 1, 2004; 172(1): 644 - 650.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Reddy, T. Teshima, G. Hildebrandt, D. L. Williams, C. Liu, K. R. Cooke, and J. L.M. Ferrara
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
Blood, April 1, 2003; 101(7): 2877 - 2885.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
D. Arnold, C. Wasem, P. Juillard, P. Graber, I. Cima, C. Frutschi, S. Herren, S. Jakob, S. Alouani, C. Mueller, et al.
IL-18-independent cytotoxic T lymphocyte activation and IFN-{gamma} production during experimental acute graft-versus-host disease
Int. Immunol., May 1, 2002; 14(5): 503 - 511.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. R. Wingard, G. B. Vogelsang, and H. J. Deeg
Stem Cell Transplantation: Supportive Care and Long-Term Complications
Hematology, January 1, 2002; 2002(1): 422 - 444.
[Abstract] [Full Text]

Home page
 JEMHome page
P. Reddy, T. Teshima, M. Kukuruga, R. Ordemann, C. Liu, K. Lowler, and J. L.M. Ferrara
Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis
J. Exp. Med., November 12, 2001; 194(10): 1433 - 1440.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. H. Kono, M. S. Park, A. Szydlik, K. M. Haraldsson, J. D. Kuan, D. L. Pearson, P. Hultman, and K. M. Pollard
Resistance to Xenobiotic-Induced Autoimmunity Maps to Chromosome 1
J. Immunol., August 15, 2001; 167(4): 2396 - 2403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.